BioLingus (Cayman) Limited (SUBL)

SUBL Balance Sheet

Financials in millions USD. Fiscal year is May - April.

Year Ending	TTM	Apr 30, 2022	Apr 30, 2021
Cash & Equivalents	0.1	0.16	0.11
Short-Term Investments	-	0.04	0.13
Cash & Cash Equivalents	0.1	0.2	0.24
Cash Growth	-	-17.19%	-
Other Current Assets	0.05	0.07	0.14
Total Current Assets	0.14	0.27	0.38
Goodwill and Intangibles	-	0.09	0.37
Total Long-Term Assets	-	0.09	0.37
Total Assets	-	0.36	0.74
Accounts Payable	-	0.5	0.84
Current Debt	-	5.02	2.83
Other Current Liabilities	6.72	0	1
Total Current Liabilities	6.72	5.53	4.67
Long-Term Debt	-	1.6	2.45
Other Long-Term Liabilities	-	0.89	0
Total Long-Term Liabilities	-	2.49	2.45
Total Liabilities	-	8.02	7.11
Total Debt	6.36	6.63	5.27
Debt Growth	-	25.65%	-
Retained Earnings	-	-7.75	-6.33
Comprehensive Income	-	0.09	-0.04
Shareholders' Equity	-7.66	-7.66	-6.37
Net Cash / Debt	-6.26	-6.43	-5.03
Working Capital	-6.58	-5.26	-4.29

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).